STVN
+0.0 · +0.00%
USD · NYSE

Stevanato Group SpA(STVN) Stock Analysis | Healthcare

USD --+0.00%
Reward47Moderate
Risk38Moderate
75%Data
Profitless Growth
Market Cap:5.60Bn
ⓘ
Reward Rating
47
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
38
Moderate
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on STVN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Stevanato Group SpA?

engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

AI Brief Pro

The brief on Stevanato Group SpA

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Stevanato Group SpA?

engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 5.60B, and a P/E ratio of 36.0x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (47)

Similar stocks to compare

A short list of Medical Instruments & Supplies names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Instruments & Supplies
P/E Ratio35.9825
Beta0.746
Insider Activity
12M windowNo data
No insider activity data available for this ticker.